U.S. markets closed

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.8600-0.1800 (-4.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.0400
Open4.0400
Bid3.8700 x 4000
Ask3.8800 x 2900
Day's Range3.8100 - 4.1000
52 Week Range0.9100 - 4.8000
Volume4,413,590
Avg. Volume6,490,723
Market Cap668.888M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Sesen Bio Announces Positive Outcome From Late-Cycle FDA Meeting For Vicineum Application
    Benzinga

    Sesen Bio Announces Positive Outcome From Late-Cycle FDA Meeting For Vicineum Application

    Sesen Bio Inc (NASDAQ: SESN) participated in a Late-Cycle Meeting with the FDA regarding the marketing application seeking approval for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA confirmed that there is no Advisory Committee meeting planned at this time. No issues related to risk management have been identified to date. No post-marketing requirements, including a confirmatory trial, have been identified as necessary at this time. The Company believes the ap

  • Sesen Bio Is a Low Priced Stock With Good Technical 'Bones'
    TheStreet.com

    Sesen Bio Is a Low Priced Stock With Good Technical 'Bones'

    During Monday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about Sesen Bio : "Take some profits off the table," was Cramer's advice about the company that was formerly Eleven Biotherapeutics. Sesen Bio is a late-stage clinical company that provides a targeted protein therapeutics (TPT) platform. In this daily bar chart of SESN, below, we can see how prices have charged higher the past 12 months.

  • Is the Options Market Predicting a Spike in Sesen Bio (SESN) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Sesen Bio (SESN) Stock?

    Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.